MammaPrint: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | |||
Revision as of 03:37, 11 February 2025
MammaPrint is a genomic test that analyzes the activity of certain genes in early-stage breast cancer. MammaPrint uses the science of genomics to measure the activity of 70 genes, providing information that can help doctors make treatment decisions.
Overview
MammaPrint was developed by Agendia, a leading molecular diagnostics company. It is a 70-gene signature assay and is used to predict the risk of metastasis in breast cancer patients. The test is based on the RNA expression profile of these 70 genes.
Clinical Use
MammaPrint is used in the clinical setting to help doctors determine the likelihood of breast cancer recurrence and the benefit of chemotherapy. The test can be used for patients with stage 1 or stage 2 breast cancer that is ER-positive or ER-negative, and who have either node-negative or node-positive disease.
Test Results
MammaPrint test results are reported as either low risk or high risk. A low risk result means that the patient's cancer has a low risk of recurrence, while a high risk result means that the patient's cancer has a high risk of recurrence.
Limitations
While MammaPrint can provide valuable information, it has limitations. It is not suitable for all patients, and the results should be interpreted in the context of other clinical and pathological factors.
